S
Silvio Veronese
Researcher at University of Milan
Publications - 105
Citations - 14769
Silvio Veronese is an academic researcher from University of Milan. The author has contributed to research in topics: KRAS & Colorectal cancer. The author has an hindex of 40, co-authored 100 publications receiving 12914 citations. Previous affiliations of Silvio Veronese include University of Turin & University of Modena and Reggio Emilia.
Papers
More filters
Journal ArticleDOI
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Chetan Bettegowda,Chetan Bettegowda,Mark Sausen,Rebecca J. Leary,Isaac Kinde,Yuxuan Wang,Nishant Agrawal,Nishant Agrawal,Bjarne Bartlett,Bjarne Bartlett,Hao Wang,Brandon Luber,Rhoda M. Alani,Emmanuel S. Antonarakis,Nilofer S. Azad,Alberto Bardelli,Henry Brem,John L. Cameron,Clarence Lee,Leslie A. Fecher,Leslie A. Fecher,Gary L. Gallia,Peter Gibbs,Dung T. Le,Dung T. Le,Robert L. Giuntoli,Michael Goggins,Michael D. Hogarty,Matthias Holdhoff,Seung-Mo Hong,Seung-Mo Hong,Yuchen Jiao,Hartmut Juhl,Jenny J. Kim,Giulia Siravegna,Daniel A. Laheru,Calogero Lauricella,Michael Lim,Evan J. Lipson,Suely Kazue Nagahashi Marie,George J. Netto,Kelly S. Oliner,Alessandro Olivi,Louise Olsson,Gregory J. Riggins,Andrea Sartore-Bianchi,Kerstin Schmidt,le-Ming Shih,Sueli Mieko Oba-Shinjo,Salvatore Siena,Dan Theodorescu,Jeanne Tie,Timothy T. Harkins,Silvio Veronese,Tian Li Wang,Jon D. Weingart,Christopher L. Wolfgang,Laura D. Wood,Dongmei Xing,Ralph H. Hruban,Jian Wu,Peter J. Allen,C. Max Schmidt,Michael A. Choti,Victor E. Velculescu,Kenneth W. Kinzler,Bert Vogelstein,Nickolas Papadopoulos,Luis A. Diaz,Luis A. Diaz +69 more
TL;DR: The ability of circulating tumor DNA (ctDNA) to detect tumors in 640 patients with various cancer types was evaluated and suggested that ctDNA is a broadly applicable, sensitive, and specific biomarker that can be used for a variety of clinical and research purposes.
Journal ArticleDOI
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Sandra Misale,Rona Yaeger,Sebastijan Hobor,Elisa Scala,Manickam Janakiraman,David Liska,Emanuele Valtorta,Roberta Schiavo,Michela Buscarino,Giulia Siravegna,Katia Bencardino,Andrea Cercek,Chin Tung Chen,Silvio Veronese,Carlo Zanon,Andrea Sartore-Bianchi,Marcello Gambacorta,Margherita Gallicchio,Efsevia Vakiani,Valentina Boscaro,Enzo Medico,Martin R. Weiser,Salvatore Siena,Federica Di Nicolantonio,David B. Solit,Alberto Bardelli +25 more
TL;DR: KRAS mutations are identified as frequent drivers of acquired resistance to cetuximab in colorectal cancers, indicate that the emergence of KRAS mutant clones can be detected non-invasively months before radiographic progression and suggest early initiation of a MEK inhibitor as a rational strategy for delaying or reversing drug resistance.
Journal ArticleDOI
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study
Mauro Moroni,Silvio Veronese,Silvia Benvenuti,Giovanna Marrapese,Andrea Sartore-Bianchi,Federica Di Nicolantonio,Marcello Gambacorta,Salvatore Siena,Alberto Bardelli +8 more
TL;DR: It is proposed that the response to antiEGFR treatment has a genetic basis and suggest that patients might be selected for treatment on the basis of EGFR copy number.
Journal ArticleDOI
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
Giulia Siravegna,Benedetta Mussolin,Michela Buscarino,Giorgio Corti,Andrea Cassingena,Giovanni Crisafulli,Agostino Ponzetti,Chiara Cremolini,Alessio Amatu,Calogero Lauricella,Simona Lamba,Sebastijan Hobor,Antonio Avallone,Emanuele Valtorta,Giuseppe Rospo,Enzo Medico,Valentina Motta,Carlotta Antoniotti,Fabiana Tatangelo,Beatriz Bellosillo,Silvio Veronese,Alfredo Budillon,Clara Montagut,Patrizia Racca,Silvia Marsoni,Alfredo Falcone,Ryan B. Corcoran,Federica Di Nicolantonio,Fotios Loupakis,Salvatore Siena,Andrea Sartore-Bianchi,Alberto Bardelli +31 more
TL;DR: The results indicate that the CRC genome adapts dynamically to intermittent drug schedules and provide a molecular explanation for the efficacy of rechallenge therapies based on EGFR blockade.
Journal ArticleDOI
Oncogenic Activation of the RAS/RAF Signaling Pathway Impairs the Response of Metastatic Colorectal Cancers to Anti–Epidermal Growth Factor Receptor Antibody Therapies
Silvia Benvenuti,Andrea Sartore-Bianchi,Federica Di Nicolantonio,Carlo Zanon,Mauro Moroni,Silvio Veronese,Salvatore Siena,Alberto Bardelli +7 more
TL;DR: It is shown that mutations activating the RAS/RAF signaling pathway are also predictive and prognostic indicators in mCRC patients, being inversely correlated with response to anti-EGFR mAbs.